SG10201701933XA - Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers - Google Patents
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancersInfo
- Publication number
- SG10201701933XA SG10201701933XA SG10201701933XA SG10201701933XA SG10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor alpha
- folate receptor
- diagnostic
- prognostic marker
- expressing cancers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41049710P | 2010-11-05 | 2010-11-05 | |
US201161508444P | 2011-07-15 | 2011-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201701933XA true SG10201701933XA (en) | 2017-05-30 |
Family
ID=45003076
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201701933XA SG10201701933XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
SG2013030424A SG189957A1 (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
SG10201509145XA SG10201509145XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013030424A SG189957A1 (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
SG10201509145XA SG10201509145XA (en) | 2010-11-05 | 2011-11-04 | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120207771A1 (en) |
EP (2) | EP2635304B1 (en) |
JP (2) | JP6224456B2 (en) |
KR (2) | KR101931936B1 (en) |
CN (2) | CN103687618A (en) |
AU (3) | AU2011323124C1 (en) |
BR (1) | BR112013011072B1 (en) |
CA (1) | CA2816991C (en) |
ES (2) | ES2780192T3 (en) |
IL (2) | IL225871B (en) |
MX (2) | MX368394B (en) |
RU (2) | RU2764592C2 (en) |
SG (3) | SG10201701933XA (en) |
WO (1) | WO2012061759A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2607444C (en) * | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
KR101637138B1 (en) | 2010-02-24 | 2016-07-06 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US20120189620A1 (en) * | 2011-01-21 | 2012-07-26 | Emory University | Methods for treating non-functioning pituitary adenoma |
EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
BR112013025415B1 (en) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | use of a folate antireceptor immunoconjugate 1 (folr1) |
TR201802838T4 (en) | 2011-07-15 | 2018-03-21 | Eisai R&D Man Co Ltd | Anti-folate receptor alpha antibodies and their use. |
JP6122948B2 (en) | 2012-05-15 | 2017-04-26 | モルフォテック, インコーポレイテッド | Methods for the treatment of gastric cancer |
RU2668824C2 (en) * | 2012-08-31 | 2018-10-02 | Иммьюноджен Инк. | Diagnostic assays and kits for detection of folate receptor 1 |
US20160311921A1 (en) | 2013-06-20 | 2016-10-27 | Morphotek ,Inc. | Methods for treatment of ovarian cancer |
MX371496B (en) | 2013-08-30 | 2020-01-31 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1. |
DK3055332T3 (en) * | 2013-10-08 | 2019-12-09 | Immunogen Inc | ANTI-FOLR1 immunoconjugate-DOSAGE REGIMES |
ES2835823T3 (en) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Combination of T-cell activating bispecific antigen-binding molecules for CD3 and folate receptor 1 (FolR1) and PD-1 axis-binding antagonists |
EP3283886B1 (en) | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
CA2994888A1 (en) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Therapeutic combinations comprising anti-folr1 immunoconjugates |
MX2019001756A (en) | 2016-08-12 | 2019-05-09 | L E A F Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof. |
JP7072571B2 (en) | 2016-11-23 | 2022-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Antifolate acceptor alpha antibody and its use |
CN107446021B (en) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | Folate receptor alpha specific binding peptide 5 and application thereof |
CN107353325B (en) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | Folate receptor alpha specific binding peptide 1 and application thereof |
CN107446020B (en) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | Folacin receptor alpha specific peptide 2 and its application |
CN111108385A (en) * | 2017-09-05 | 2020-05-05 | 伊缪诺金公司 | Method for detecting folate receptor 1 in a patient sample |
WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | Alpha polyglutamated pralatrexate and uses thereof |
CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
KR20200132900A (en) * | 2018-03-13 | 2020-11-25 | 페인스 테라퓨틱스 인코포레이티드 | Anti-folate receptor 1 antibody and uses thereof |
JP2022523564A (en) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | Data compression and communication using machine learning |
MA55818A (en) | 2019-04-29 | 2022-03-16 | Immunogen Inc | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES |
US20230112620A1 (en) * | 2021-06-04 | 2023-04-13 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
CN117700557B (en) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | Antibody or antigen binding fragment specifically binding to folate receptor alpha |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
DE69334258D1 (en) | 1992-08-21 | 2009-02-26 | Univ Bruxelles | Immunoglobulins without a light chain |
EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
ATE220114T1 (en) | 1993-03-19 | 2002-07-15 | Sequenom Inc | DNA SEQUENCE DETERMINATION BY MASS SPECTROMETRY THROUGH THE DEGRADATION PATH WITH EXONUCLEASE |
PT971946E (en) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selection of proteins using rna-protein fusions |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6933108B2 (en) * | 1999-12-09 | 2005-08-23 | The Regents Of The University Of California | Methods and compositions for use in the treatment of filovirus mediated disease conditions |
AU2002213720A1 (en) * | 2000-11-01 | 2002-05-15 | Mount Sinai Hospital | Detection of ovarian cancer |
US20100120078A1 (en) * | 2001-08-16 | 2010-05-13 | Tony Baker | Urine Stabilization System |
CA2784450C (en) * | 2001-11-13 | 2016-09-13 | Id Biomedical Corporation | Polypeptides of pseudomonas aeruginosa |
AU2003253589A1 (en) * | 2002-03-26 | 2003-11-10 | Centocor, Inc. | Epitope mapping using nuclear magnetic resonance |
WO2004082463A2 (en) * | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
JP2007537709A (en) * | 2003-05-23 | 2007-12-27 | モーフオテク・インコーポレーテツド | Monoclonal antibodies that specifically bind tumor antigens |
US20080113344A1 (en) * | 2003-10-28 | 2008-05-15 | Ralph Wirtz | Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment |
WO2005080431A2 (en) | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2006105141A1 (en) * | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
CA2607444C (en) * | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
KR20080114689A (en) * | 2006-02-09 | 2008-12-31 | 유니버시티 오브 사우스 플로리다 | Detection of cancer by elevated levels of bcl-2 |
US8486412B2 (en) * | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
US20100216718A1 (en) * | 2007-10-19 | 2010-08-26 | Cell Signaling Technology, Inc. | Cancer Classification and Methods of Use |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
EP2606353A4 (en) * | 2010-08-18 | 2014-10-15 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
-
2011
- 2011-11-04 KR KR1020137014442A patent/KR101931936B1/en active IP Right Grant
- 2011-11-04 WO PCT/US2011/059411 patent/WO2012061759A2/en active Application Filing
- 2011-11-04 JP JP2013537884A patent/JP6224456B2/en active Active
- 2011-11-04 SG SG10201701933XA patent/SG10201701933XA/en unknown
- 2011-11-04 MX MX2016011546A patent/MX368394B/en unknown
- 2011-11-04 CN CN201180064293.4A patent/CN103687618A/en active Pending
- 2011-11-04 AU AU2011323124A patent/AU2011323124C1/en active Active
- 2011-11-04 ES ES16186634T patent/ES2780192T3/en active Active
- 2011-11-04 RU RU2017129266A patent/RU2764592C2/en active
- 2011-11-04 ES ES11785862.1T patent/ES2627061T3/en active Active
- 2011-11-04 RU RU2013125772A patent/RU2630608C2/en active
- 2011-11-04 EP EP11785862.1A patent/EP2635304B1/en active Active
- 2011-11-04 SG SG2013030424A patent/SG189957A1/en unknown
- 2011-11-04 CN CN201710961050.XA patent/CN108562744A/en active Pending
- 2011-11-04 US US13/289,892 patent/US20120207771A1/en not_active Abandoned
- 2011-11-04 CA CA2816991A patent/CA2816991C/en active Active
- 2011-11-04 SG SG10201509145XA patent/SG10201509145XA/en unknown
- 2011-11-04 EP EP16186634.8A patent/EP3130605B1/en active Active
- 2011-11-04 MX MX2013005067A patent/MX343607B/en active IP Right Grant
- 2011-11-04 KR KR1020187036506A patent/KR102057438B1/en active IP Right Grant
- 2011-11-04 BR BR112013011072-4A patent/BR112013011072B1/en active IP Right Grant
-
2013
- 2013-04-21 IL IL225871A patent/IL225871B/en active IP Right Grant
-
2016
- 2016-05-25 AU AU2016203408A patent/AU2016203408A1/en not_active Abandoned
-
2017
- 2017-10-04 JP JP2017194027A patent/JP6554152B2/en active Active
-
2018
- 2018-03-12 AU AU2018201760A patent/AU2018201760B2/en active Active
- 2018-07-13 IL IL260590A patent/IL260590B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260590B (en) | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers | |
HK1135940A1 (en) | Self-powered coordinate probe | |
EP2585833A4 (en) | Methods for detecting cancer | |
EP2630917A4 (en) | Breast measurement apparatus | |
EP2592383A4 (en) | Information providing apparatus | |
EP2569446A4 (en) | Diagnostic markers for neuropsychiatric disease | |
GB201414085D0 (en) | Breast cancer diagnosis and indication marker | |
EP2636040A4 (en) | Copyback operations | |
EP2748608A4 (en) | Lung cancer tests | |
EP2634544A4 (en) | Collective chute for combination scale | |
GB201012590D0 (en) | Methods for diagnosing cancer | |
EP2524702A4 (en) | Diagnostic for cancer | |
EP2495561A4 (en) | Anticancer agent sensitivity-determining marker | |
EP2686447A4 (en) | Prognostic marker sets for prostate cancer | |
ZA201200888B (en) | New tumor marker | |
EP2486154A4 (en) | Diagnostic and prognostic markers for cancer | |
EP2531616A4 (en) | Diagnostic and prognostic assay for breast cancer | |
GB201414102D0 (en) | Colorectal cancer diagnosis and indication marker | |
GB2477687B (en) | X-ray marker | |
GB0908071D0 (en) | Marker | |
EP2735571A4 (en) | Antibody for colorectal cancer marker | |
PT2386459E (en) | Train location system | |
GB0905964D0 (en) | Marker | |
TWI563256B (en) | Marker for colon cancer and method for detecting colon cancer | |
GB2484553B (en) | A tunnelling device |